CXCL8 and neoplasm: A phase I clinical trial (NCT02536469) was completed, which tested the anti-tumor efficacy of humanized anti-IL-8 monoclonal antibodies in solid tumors, providing possibilities to utilize the IL-8 antibody to abrogate CSCs in HCC [139].